Omeprazol Ab (Omeprazole)

Omeprazol Ab is a proton pump inhibitor that acts on the gastric acid secretion pathway, providing relief in several acid‑related disorders.

• Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining.
• Peptic ulcer disease: supports ulcer healing by maintaining a less acidic gastric environment.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare endocrine disorder.

• Omeprazole irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells, inhibiting the final step of acid production. This suppression of gastric acid secretion lowers gastric pH, allowing mucosal healing and symptom relief.

Adverse reactions to Omeprazole may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Headache: mild, transient headache reported by some patients.
• Diarrhoea: loose stools occurring during the initial weeks of treatment.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach region.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Clostridioides difficile infection: persistent watery diarrhoea.
• Low magnesium levels: muscle cramps, irregular heartbeat, or seizures.
• Fracture risk: increased incidence of hip, wrist or spine fractures with long‑term use.
• Liver enzyme elevation: signs of hepatic dysfunction.
• Acute interstitial nephritis: kidney inflammation presenting with fever and flank pain.

When prescribing Omeprazol Ab, clinicians should consider several safety aspects to optimise patient outcomes.

• Assess renal and hepatic function: adjust use if impairment is present.
• Review concomitant medications: potential for drug‑drug interactions.
• Monitor long‑term users: watch for bone density loss and nutrient deficiencies.
• Use cautiously in pregnancy: evaluate risk‑benefit ratio.
• Avoid in patients with known hypersensitivity to omeprazole or other PPIs.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the plasma concentrations of several co‑administered drugs, requiring attention to interaction potential.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk.
• Atazanavir: decreased antiviral absorption, compromising HIV therapy.
• Methotrexate (high dose): increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely)

• Warfarin: possible alteration of INR values, requiring closer monitoring.
• Digoxin: modest increase in serum levels.
• Phenytoin: reduced serum concentration, potentially lowering seizure control.